Download Document

Educational modules for innovational
drug development researchers
M.V.Lomonosov Moscow State
University
- Faculty of bioengineering and bioinformatics
- Faculty of fundamental medicine
Educational modules
• Preclinical safety
assessment of
innovational
biosimilars
15 credits
• Mitochondriatargeted drugs
development
15 credits
Preclinical safety assessment of
innovational biosimilars
Laboratory of Biological Testing
Aaalac license since 2005
GLP compliance certificate
since 2013
Staff includes more than 40 exceptionally
dedicated professionals:
16 research scientists (2 D.Sci., 7 Ph.D.),
6 engineers, and 16 technicians.
Research staff members are educated in
physiology, veterinary surgery,
biochemistry, pharmacology and
pharmaceutics.
Possibility to use SPF animals.
All research protocols involving animals are reviewed
by Institutional Animal Care and Use Committee.
17 laboratory rooms,
13 animal rooms.
Controlled conditions
of animal housing
and management.
Module elements
• Laboratory animals in biomedical
research
• Medical safety trials
• Good Laboratory Practice (GLP)
principles
• Experimental research basic principles
Mitochondria-targeted drugs
development
Mitochondrion
Cell
Aging
Cancer
Programmed
cell death
Mitochondrial
diseases
Metabolic
disorders
Inflammation
Oxidative
stress
Belozersky Institute,
Moscow State University
- One of the major
research and educational
units of the Lomonosov
Moscow State University
-50 years of
mitochondrial research
- Excellent modern
equipment
Faculty of bioengineering and
bioinformatics,
Moscow State University
• Innovational
educational
program
• Special focus on:
- mathematics
- research
- biology of
mitochondria
Practical implementation
New type of mitochondriatargeted antioxidants: SkQ
Antioxidant
(plastoquinone)
«Skulachev Ion»
triphenylphosphonium
Fluorescent SkQ specifically stains
mitochondria in HeLa cells
SkQ1 prevents accelerated aging in mutant mice
B.Cannon,
Stockholm
SkQ1 cures eye disease in
rats
N.G. Kolosova,
Novosibirsk
Clinical trials (dry eye syndrom) of SkQ1 eye drops.
Percent of patients reporting complete recovery
60%
60%
***
Tears
SkQ1
naturale
"слеза натуральная"
50%
40%
SkQ1
30%
20%
20%
15% 15%
10%
0% 0%
0% 0%
0% 0%
3%
0%
3%
5%
0%
0
1
2
3
Days of treatment
*** p<0,001
7
14
21
2012: first approved and marketed
mitochondria-targeted drug
• Eye drops
155 ng SkQ1 per ml
Registration number:
ЛП-001355, 13 December 2011 г.
Module elements
• Molecular biology of mitochondria
• Structure and function of mitochondria
• Mitochondria in programmed cell death
• Mitochondria-targeted drugs:
development principles